Not Yet RecruitingPhase 2ACTRN12605000674639

HPV VLP as adjunct therapy for genital warts

A phase 1b, multicentre study of CICRVax6 HPV6L1 VLPs as therapy for genital warts

Sponsor

Centre for Immunology and Cancer Research, University of Queensland

Enrollment

480 participants

Start Date

Nov 1, 2005

Study Type

Interventional

Conditions

Patients with persistent or recurrent genital warts

Summary

Anticipated trial start date: February 2006 (Brisbane), November 2005 (Wenzhou China) Target sample size: 240 (120 male, 120 female) at each site

Eligibility

Sex: Both males and females

Plain Language Summary

Simplified for easier understanding

This study tests whether an HPV vaccine (virus-like particles) can help treat genital warts that have persisted or come back after standard treatment. Both men and women who have had genital warts for at least three months and have already tried at least one round of conventional treatment may be eligible. Participants would receive the vaccine along with further standard wart treatment.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Vaccine will be given twice over one month to patients, concurrently with administration of conventional destructive therapy. Patients with genital warts will all undergo conventional destructive therapy and will additionally be randomized in block of 4 to receive either CICRVax6 (at one of three doses) or placebo twice at week 0 and week 4.

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12605000674639